RESEARCH
PUBLICATIONS
NEXTBIO COMMUNITY
Results presented below are derived from data collected from over 475 news feeds.
Click on one of these terms to refine your search
1 to 10 of 20 stories
-
Abbott suing Impax Labs over generic TriCor
Biotech News. - October 31, 2009Impax Laboratories Inc. confirmed Friday it is challenging the patents on Abbott Laboratories' cholesterol drug TriCor, and that Abbott is suing Impax for patent infringement.
-
[Comment] Fenofibrate and risk of minor amputations in diabetes
Lancet. - May 21, 2009In The Lancet today, Kushwin Rajamani and co-workers report a further analysis of the FIELD trial of fenofibrate in patients with type 2 diabetes, which shows a large effect of treatment on the rate of minor amputations during the 5-year study. This new report adds important informati…
-
Fenofibrate Cuts Amputation Risk in Diabetes
WebMD. - May 21, 2009Treating type 2 diabetes patients with a cholesterol-lowering drug called fenofibrate cuts the risk of a first diabetes-related limb amputation by 36%, according to a new study.
-
Fenofibrate Cuts Risk of Diabetes-Related Amputation (CME/CE)
MedPageToday.com. - May 21, 2009LITTLE FALLS, N.J. (MedPage Today) -- Fenofibrate reduces the risk of amputation for patients with type 2 diabetes, a large randomized trial showed.
-
Fenofibrate Reduces Risk Of First Amputation For Type 2 Diabetics By 36%
Medical News Today. - May 22, 2009Using fenofibrate to lower blood fats in people with type 2 diabetes reduces the risk of a first diabetes-related amputation by 36%. This is among the conclusions of the FIELD study, reported in an Article in this week's diabetes special issue of The Lancet.
-
Correlation of Non High-Density Lipoprotein Cholesterol and Low-Density Lipoprotein Cholesterol With Apolipoprotein B During Simvastatin + Fenofibrate Therapy in Patients With Combined Hyperlipidemia (A Subanalysis of the SAFARI Trial)
American journal. - August 14, 2009Guidelines have recommended non high-density lipoprotein (non-HDL) cholesterol as a secondary target for therapy after the low-density lipoprotein (LDL) cholesterol goals have been met in patients with hypertriglyceridemia; non-HDL cholesterol is viewed as a surrogate for apolipoprote…
-
Fenofibrate curbs heart disease in diabetics
Reuters. - March 20, 2009NEW YORK (Reuters Health) - Treatment with fenofibrate, a cholesterol-lowering drug, reduces the risk of heart disease in patients with type 2 diabetes and components of the metabolic syndrome, researchers report in the journal Diabetes Care.
-
[Articles] Effect of fenofibrate on amputation events in people with type 2 diabetes mellitus (FIELD study): a prespecified analysis of a randomised controlled trial
Lancet. - May 21, 2009Amputations in people with type 2 diabetes mellitus substantially impair their quality of life and impose high costs on health-care systems. Our aim was to assess the effect of fenofibrate on amputation events in a large cohort of patients with type 2 diabetes.
-
Fenofibrate Helps to Protect Diabetes Patients
Associated Content. - January 22, 2009Results from the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study has shown that treatment with fenofibrate helps in the prevention of cardiovascular disease in diabetics.Content Producer: Azlan HanafiPublished: Jan 22, 2009
-
Diabetes Patients With High Triglycerides And Low HDL Cholesterol Get The Most Benefit From Fenofibrate Treatment: New Data From The FIELD Study
Medical News Today.Fenofibrate treatment reduces cardiovascular disease (CVD) risk (defined by total cardiovascular events: the composite of cardiovascular death, myocardial infarction, stroke, and coronary and carotid revascularization) in patients with type 2 diabetes and atherogenic dyslipidemia, tha…
